Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

Nyxoah announced the first patient implantation in BREATHE, a U.S. post-approval study of its Genio system for obstructive sleep apnea treatment. The multicenter study will implant up to 229 patients across 25 U.S. centers and follow them for up to five years to evaluate long-term safety and effectiveness of the bilateral hypoglossal nerve stimulation therapy in real-world clinical practice.

09/07/2026, 4:05 PM • GlobeNewswire

Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®

Nyxoah announced the first patient implantation in BREATHE, a post-approval U.S. study of its Genio® system for obstructive sleep apnea treatment. The study will implant up to 229 patients across 25 U.S. centers over five years to evaluate long-term safety and efficacy in real-world clinical practice. The first procedure was performed by Dr. Rolando Molina at South Florida ENT Associates.

09/07/2026, 4:05 PM • GlobeNewswire

Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has announced an extraordinary shareholders' meeting scheduled for July 9, 2026, to vote on renewing the board of directors' authorization to increase the company's share capital. The meeting will allow shareholders to participate in-person or via video conference, with voting available through proxy or mail.

06/19/2026, 4:30 PM • GlobeNewswire

Invitation à assister à l'assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le 9 juillet 2026

Nyxoah has secured $15 million in non-dilutive debt funding from the European Investment Bank, complementing the company's June equity raise and bringing total capital raised to $110 million. The company is also holding an extraordinary general shareholders' meeting on July 9, 2026, to renew authorization for capital increases.

06/19/2026, 4:30 PM • GlobeNewswire

Information on the total number of voting rights and shares

Nyxoah SA completed an underwritten public offering, issuing 55,232,558 new shares to accelerate the U.S. commercial launch of its Genio product. The company secured $110 million in aggregate financings. Following the offering, the total number of voting rights increased to 99,926,284 ordinary shares.

06/10/2026, 5:00 PM • GlobeNewswire

Informations sur le nombre total de droits de vote et d'actions

Nyxoah SA completed an underwritten public offering of 55.2 million new shares to accelerate the U.S. commercial launch of its Genio product, raising $110 million in aggregate financing. The offering included both public shares in the U.S. and private placements to qualified investors internationally, including the EU.

06/10/2026, 5:00 PM • GlobeNewswire

Publication relative à des notifications de transparence

Nyxoah SA announced that it received a transparency notification on March 19, 2026, regarding Robert Taub and his related entity Robelga SRL crossing the 3% voting rights threshold on December 30, 2025. Robert Taub and his controlled entities now hold 4,360,800 voting rights (10.14% of total voting rights), comprising 4,310,800 voting rights attached to securities and 50,000 assimilated financial instruments.

03/20/2026, 5:30 PM • GlobeNewswire

Publication relating to transparency notifications

Nyxoah SA announced that it received a transparency notification on March 19, 2026, regarding Robert Taub and Robelga SRL crossing above the 3% threshold on December 30, 2025. The combined holding represents 10.14% of total voting rights (4,360,800 voting rights out of 43,026,460), consisting of 4,310,800 voting rights linked to securities and 50,000 equivalent financial instruments in the form of warrants.

03/20/2026, 5:30 PM • GlobeNewswire

Publication relating to transparency notification

Nyxoah SA announced that BNP Paribas Asset Management Europe SAS crossed below the 3% voting rights threshold on March 9, 2026, reducing its holding from 1,409,791 to 1,307,817 voting rights (3.00% of total voting rights). The notification was filed in accordance with Belgian transparency disclosure requirements.

03/13/2026, 5:30 PM • GlobeNewswire

Publication relative à une notification de transparence

Nyxoah SA announced that BNP Paribas Asset Management Europe SAS has crossed below the 3% voting rights threshold, reducing its holding from 1,409,719 to 1,307,817 voting rights (3.00% of total voting rights) as of March 9, 2026. The reduction was triggered by an acquisition or disposal of securities conferring voting rights.

03/13/2026, 5:30 PM • GlobeNewswire

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands

Nyxoah launched its Genio® system in the Netherlands, performing first successful implants at OLVG West and Zuyderland hospitals, offering an alternative treatment for Obstructive Sleep Apnea (OSA) patients who cannot tolerate CPAP.

12/17/2025, 1:05 AM • GlobeNewswire

Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays-Bas

Nyxoah successfully launched its Genio® neurostimulation system for Obstructive Sleep Apnea treatment in the Netherlands, with first implantations at OLVG West and Zuyderland hospitals, offering patients an alternative to CPAP therapy.

12/17/2025, 1:05 AM • GlobeNewswire

Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

Nyxoah announced CMS has increased Medicare reimbursement for its Genio hypoglossal nerve stimulation therapy by 48% for hospital outpatient departments and 58% for ambulatory surgery centers in 2026, which is expected to support broader therapy adoption.

11/26/2025, 1:45 AM • GlobeNewswire

La Thérapie Genio® de Nyxoah Bénéficie d'une Augmentation Significative du Remboursement Medicare en 2026 en Vertu de la Règle Finale du CMS

Nyxoah announced a substantial Medicare reimbursement increase for its Genio® sleep apnea treatment in 2026, with hospital outpatient services reimbursement rising 48% to $45,000 and ambulatory surgery center reimbursement increasing 58% to $42,373.

11/26/2025, 1:45 AM • GlobeNewswire

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio

Nyxoah secured $77 million in financing through a private placement, registered direct offering, and convertible bond to support U.S. commercialization of its Genio system for treating Obstructive Sleep Apnea (OSA).

11/13/2025, 7:30 PM • GlobeNewswire